Related Experiment Video
Updated: Jan 25, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
RANKL is a therapeutic target of bone destruction in rheumatoid arthritis
1Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Abstract:
Although remarkable advances have been made in the treatment of rheumatoid arthritis (RA), novel therapeutic options with different mechanisms of action and fewer side effects have been expected. Recent studies have demonstrated that bone-resorbing osteoclasts are critically involved in the bone destruction associated with RA. Denosumab, a human antibody against receptor activator of nuclear factor-kappa B ligand (RANKL), efficiently suppressed the progression of bone erosion in patients with RA by suppressing osteoclast differentiation and activation in several clinical studies, although it had no effect on inflammation or cartilage destruction. Denosumab, in combination with anti-rheumatic drugs, is considered a pivotal therapeutic option for the prevention of bone destruction in RA.
Insights
Denosumab effectively prevents bone erosion in rheumatoid arthritis (RA) by inhibiting osteoclasts. This treatment, targeting receptor activator of nuclear factor-kappa B ligand (RANKL), offers a new way to protect bones in RA patients.
Area of Science:
- Rheumatology
- Immunology
- Bone Biology
Background:
- Rheumatoid arthritis (RA) causes significant bone destruction.
- Osteoclasts play a key role in RA-related bone loss.
- Existing RA treatments have limitations, necessitating novel options.
Purpose of the Study:
- To evaluate Denosumab's efficacy in preventing bone destruction in RA.
- To investigate Denosumab's mechanism of action on osteoclasts in RA.
Main Methods:
- Clinical studies involving RA patients treated with Denosumab.
- Assessment of osteoclast differentiation and activation markers.
- Evaluation of bone erosion progression.
Main Results:
- Denosumab significantly suppressed osteoclast activity.
- Bone erosion progression was efficiently halted by Denosumab.
- Denosumab did not impact inflammation or cartilage destruction.
Conclusions:
- Denosumab is a promising therapeutic option for preventing bone destruction in RA.
- Targeting RANKL with Denosumab offers a specific approach to bone protection in RA.
- Combination therapy with Denosumab and other anti-rheumatic drugs may be pivotal for RA bone health.
More Related Videos
06:31Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis
Published on: October 6, 2023
09:31Generation of Induced-pluripotent Stem Cells Using Fibroblast-like Synoviocytes Isolated from Joints of Rheumatoid Arthritis Patients
Published on: October 16, 2016
Related Concept Videos
Non-destructive Tests for Concrete Strength
Therapeutic Index
Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
Microorganisms in Medicine and Therapeutics
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...